<DOC>
	<DOCNO>NCT01947855</DOCNO>
	<brief_summary>To evaluate efficacy empagliflozin administer orally daily postprandial glucose 24-hour glycaemic variability compare placebo give 4 week mono-therapy Japanese patient type 2 diabetes mellitus insufficient glycaemic control antidiabetic treatment .</brief_summary>
	<brief_title>Post Prandial Glucose ( PPG ) Study Empagliflozin Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criterion : Diagnosis type 2 diabetes mellitus prior inform consent Male female patient diet exercise regimen 12 week prior inform consent : drugna√Øve , define antidiabetic drug least 12 week prior inform consent , pretreated one oral antidiabetic drug ( except sulfonylurea thiazolidinedione ) ; present antidiabetic therapy unchanged least 12 week prior inform consent . ( Sulfonylurea permit pretreatment drug dose equal less half daily maximum approval dose . ) Glycosylated haemoglobin ( HbA1c ) Visit 1 ( screen ) patient without antidiabetic therapy : HbA1c &gt; =7.0 = &lt; 10.0 % patient one oral antidiabetic drug : HbA1c &gt; =7.0 = &lt; 9.5 % Exclusion criterion : Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dL ( &gt; 13.3 mmol/L ) Impaired renal function , define estimate glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73m2 ( moderate severe renal impairment , modification diet renal disease ( MDRD ) formula ) Acute coronary syndrome , stroke transient ischemic attack ( TIA ) within 12 week prior inform consent Indication liver disease , define serum level either alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase ( ALP ) 3 x upper limit normal ( ULN )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>